Braden Michael Leonard Acquires 173,730 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) major shareholder Braden Michael Leonard purchased 173,730 shares of the business’s stock in a transaction on Tuesday, July 30th. The stock was purchased at an average cost of $1.30 per share, with a total value of $225,849.00. Following the acquisition, the insider now owns 13,776,421 shares in the company, valued at $17,909,347.30. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Braden Michael Leonard also recently made the following trade(s):

• On Monday, July 22nd, Braden Michael Leonard purchased 17,716 shares of Aclaris Therapeutics stock. The stock was purchased at an average cost of $1.33 per share, with a total value of $23,562.28.
• On Thursday, July 18th, Braden Michael Leonard purchased 130,317 shares of Aclaris Therapeutics stock. The stock was purchased at an average cost of $1.30 per share, with a total value of $169,412.10.
• On Friday, July 5th, Braden Michael Leonard purchased 123,017 shares of Aclaris Therapeutics stock. The stock was purchased at an average cost of $1.15 per share, with a total value of $141,469.55.
• On Wednesday, July 3rd, Braden Michael Leonard bought 143,288 shares of Aclaris Therapeutics stock. The stock was bought at an average cost of $1.16 per share, with a total value of $166,214.08.
• On Monday, July 1st, Braden Michael Leonard bought 107,434 shares of Aclaris Therapeutics stock. The stock was bought at an average cost of $1.14 per share, with a total value of $122,474.76.
• On Thursday, June 27th, Braden Michael Leonard bought 235,000 shares of Aclaris Therapeutics stock. The stock was bought at an average cost of $1.15 per share, with a total value of $270,250.00.
• On Monday, June 17th, Braden Michael Leonard bought 150,000 shares of Aclaris Therapeutics stock. The stock was bought at an average cost of $1.13 per share, with a total value of $169,500.00.
• On Thursday, June 13th, Braden Michael Leonard bought 528,621 shares of Aclaris Therapeutics stock. The stock was bought at an average cost of $1.15 per share, with a total value of $607,914.15.
• On Tuesday, June 11th, Braden Michael Leonard bought 1,000,000 shares of Aclaris Therapeutics stock. The stock was bought at an average cost of $1.08 per share, with a total value of $1,080,000.00.

Aclaris Therapeutics Trading Up 2.3 %

ACRS stock traded up $0.03 during midday trading on Wednesday, reaching $1.34. 524,112 shares of the company’s stock traded hands, compared to its average volume of 1,223,584. The company has a 50-day simple moving average of $1.19 and a two-hundred day simple moving average of $1.20. Aclaris Therapeutics, Inc. has a 1-year low of $0.59 and a 1-year high of $10.15.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04. The firm had revenue of $2.40 million for the quarter, compared to analyst estimates of $1.99 million. Aclaris Therapeutics had a negative return on equity of 61.03% and a negative net margin of 248.28%. Analysts expect that Aclaris Therapeutics, Inc. will post -0.77 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. HC Wainwright reissued a “neutral” rating on shares of Aclaris Therapeutics in a report on Monday, July 22nd. StockNews.com raised Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, July 25th. Seven investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $22.25.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. BML Capital Management LLC boosted its position in Aclaris Therapeutics by 1,338.7% in the 1st quarter. BML Capital Management LLC now owns 9,395,934 shares of the biotechnology company’s stock valued at $11,651,000 after buying an additional 8,742,827 shares during the last quarter. Vanguard Group Inc. boosted its position in Aclaris Therapeutics by 4.4% in the 1st quarter. Vanguard Group Inc. now owns 4,929,775 shares of the biotechnology company’s stock valued at $6,113,000 after buying an additional 207,418 shares during the last quarter. Bain Capital Life Sciences Investors LLC boosted its position in shares of Aclaris Therapeutics by 2.9% in the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 3,500,000 shares of the biotechnology company’s stock worth $3,675,000 after purchasing an additional 100,000 shares during the last quarter. Monaco Asset Management SAM bought a new position in shares of Aclaris Therapeutics in the 4th quarter worth $1,028,000. Finally, BNP Paribas Financial Markets boosted its position in shares of Aclaris Therapeutics by 10.9% in the 1st quarter. BNP Paribas Financial Markets now owns 241,101 shares of the biotechnology company’s stock worth $299,000 after purchasing an additional 23,747 shares during the last quarter. 98.34% of the stock is currently owned by institutional investors.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.